News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
805,492 Results
Type
Article (73715)
Company Profile (697)
Press Release (731080)
Section
Business (227154)
Career Advice (3705)
Deals (39252)
Drug Delivery (122)
Drug Development (89121)
Employer Resources (194)
FDA (17751)
Job Trends (17083)
News (387118)
Policy (38669)
Tag
Academia (2974)
Alliances (55726)
Alzheimer's disease (1370)
Approvals (17684)
Artificial intelligence (174)
Bankruptcy (392)
Best Places to Work (12573)
Biotechnology (478)
Breast cancer (202)
Cancer (1479)
Cardiovascular disease (126)
Career advice (3153)
Cell therapy (320)
Clinical research (70857)
Collaboration (529)
Compensation (272)
COVID-19 (2815)
C-suite (122)
Data (1433)
Diabetes (196)
Diagnostics (6711)
Earnings (92072)
Employer resources (167)
Events (126263)
Executive appointments (418)
FDA (18478)
Funding (460)
Gene therapy (221)
GLP-1 (721)
Government (5005)
Healthcare (20737)
Infectious disease (2917)
Inflammatory bowel disease (126)
Interviews (722)
IPO (17574)
Job creations (4986)
Job search strategy (2588)
Layoffs (494)
Legal (9857)
Lung cancer (219)
Manufacturing (236)
Medical device (14448)
Medtech (14453)
Mergers & acquisitions (21828)
Metabolic disorders (538)
Neuroscience (1730)
NextGen Class of 2024 (7617)
Non-profit (5067)
Northern California (1749)
Obesity (305)
Opinion (249)
Patents (131)
People (63180)
Pharmaceutical (142)
Phase I (21873)
Phase II (30907)
Phase III (23309)
Pipeline (532)
Postmarket research (3253)
Preclinical (9643)
Radiopharmaceuticals (258)
Rare diseases (296)
Real estate (7138)
Regulatory (25419)
Research institute (2642)
Resumes & cover letters (579)
Southern California (1520)
Startups (4183)
United States (16428)
Vaccines (669)
Weight loss (239)
Date
Today (35)
Last 7 days (586)
Last 30 days (2574)
Last 365 days (38020)
2024 (37854)
2023 (42567)
2022 (53926)
2021 (58723)
2020 (57667)
2019 (51305)
2018 (39086)
2017 (36842)
2016 (37745)
2015 (43739)
2014 (38420)
2013 (34395)
2012 (36293)
2011 (36411)
2010 (35841)
Location
Africa (1185)
Arizona (211)
Asia (48110)
Australia (8262)
California (4063)
Canada (1485)
China (326)
Colorado (186)
Connecticut (201)
Europe (108308)
Florida (555)
Georgia (147)
Illinois (454)
Indiana (245)
Maryland (693)
Massachusetts (3246)
Michigan (197)
Minnesota (318)
New Jersey (1169)
New York (1140)
North Carolina (880)
Northern California (1749)
Ohio (156)
Pennsylvania (960)
South America (1560)
Southern California (1520)
Texas (597)
Utah (116)
Washington State (438)
805,492 Results for "shanghai pharmaceutical co ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Lakeside Holding Enters Medical Logistics Sector with Acquisition of Hupan Pharmaceutical (Hubei) Co., Ltd.
November 11, 2024
·
4 min read
Press Releases
RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody
December 23, 2024
·
7 min read
Shanghai Argo Announces Multi-Program RNAi Licenses and Strategic Collaborations with Novartis
Shanghai Argo Biopharmaceutical Co., Ltd. announced that it has entered into two exclusive license and collaboration agreements with Novartis PHARMA AG.
January 7, 2024
·
3 min read
Business
Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
Verrica Pharmaceuticals Inc. today announced that it has entered into an amendment to its existing licensing agreement with Torii Pharmaceutical Co. Ltd. (Torii), to jointly conduct a global pivotal Phase 3 clinical trial of YCANTH® for the treatment of common warts.
May 15, 2024
·
9 min read
Press Releases
Newron and EA Pharma (A Subsidiary of Eisai Co., Ltd.) Announce License Agreement for Evenamide in Japan and Other Asian Territories
December 13, 2024
·
11 min read
Press Releases
Inari Medical Announces Reimbursement Approval for ClotTriever® Thrombectomy System in Japan and New Distribution Partnership with Medikit Co., Ltd.
December 3, 2024
·
4 min read
MicuRx To Present New Data At 7th World Bronchiectasis Conference
Shanghai MicuRx Pharmaceutical Co., Ltd. announced 3 new studies will be presented at the 7th World Bronchiectasis Conference, taking place from July 4 - 6, 2024 in Dundee, Scotland.
June 19, 2024
·
2 min read
Meihua International Medical Technologies Co., Ltd. Announces Share Repurchase Program of Up to $3 million
Meihua International Medical Technologies Co., Ltd., a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China, announced that its board of directors has approved and authorized a share repurchase program of up to $3 million of the Company’s outstanding ordinary shares.
July 1, 2024
·
5 min read
Press Releases
Microbio Co., Ltd. (4128) Announces Promising Results of “MS-20" in Combination with Keytruda for Stage IIIb/IV Non-Small Cell Lung Cancer
December 16, 2024
·
2 min read
Drug Development
Rege Nephro CO., Ltd. Announces Patient Enrollment for Phase II Clinical Trial of Tamibarotene for ADPKD
Rege Nephro CO., Ltd. (https://www.regenephro.co.jp/en) has announced that patient enrollment began in April for the second stage of its Phase II clinical trial of tamibarotene as a developmental product for the treatment of autosomal dominant polycystic kidney disease (ADPKD) under the code RN-014.
May 28, 2024
·
2 min read
1 of 80,550
Next
